Business Update
Point Therapeutics reports second quarter 2006 financial results
Published in Medical Letter on the CDC and FDA, September 10th, 2006
In the second quarter of 2006, Point achieved several important milestones. It continued enrollment into two randomized Phase III double blind placebo-controlled trials of talabostat in patients with metastatic non-small cell lung cancer (NSCLC) who have previously failed platinum based therapies. Each trial will enroll approximately four hundred patients. The first trial is evaluating docetaxel (Taxotere) with and without talabostat. The second randomized Phase III trial is studying pemetrexed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Addiction Medicine
Methamphetamine injections increase dopamine turnover - Human Papillomavirus
Cytobrush samples can be used for detection of HPV but not for determining viral load - Nuclear Medicine
Radioactive Drug Research Committee regulations need updating - Q Fever Epidemiology
Epidemiology of human Q fever in United States is reported - Vector-Borne Disease
Egyptian fleas with public health significance were surveyed - Addiction Medicine
GABA-mimetic drugs differently affect cocaine-evoked hyperlocomotion and sensitization - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
